Comparative effects of BCL-2 inhibition in canine and human breast cancer in vitro models-a review

Lajos Raduly, Diana Gulei, Anca Jurj, Cristian Moldovan, Emilia Balint, Ioan Marcus, Orsolya Sarpataki, Schuyler S. Korban, Ioana Berindan-Neagoe

Research output: Contribution to journalArticlepeer-review


Breast cancer is among the leading malignant pathologies in terms of incidence and mortality rates; therefore, rapid development of effective drug treatments, particularly for triple negative breast cancer (TNBC), is of critical importance. One promising approach to speed up the process of drug discovery capitalizes on repositioning of specific therapeutic molecules used for malignancies that have similar altered molecular profiles. In this study, ABT-199, a small molecule that elicits selective inhibition of Bcl-2 and effective against chronic lymphocytic leukemia, is repositioned for treating TNBC using both human and canine breast cancer cell lines. It is observed that ABT-199 elicits similar inhibitory effects, including apoptosis, cell cycle, and migration, on both human and canine breast cancer cells.

Original languageEnglish (US)
Pages (from-to)5-22
Number of pages18
JournalAnimal Science Papers and Reports
Issue number1
StatePublished - 2022


  • breast cancer
  • canine models
  • comparative oncology
  • mammalian cancer model

ASJC Scopus subject areas

  • Biotechnology
  • Animal Science and Zoology
  • Genetics
  • General Veterinary


Dive into the research topics of 'Comparative effects of BCL-2 inhibition in canine and human breast cancer in vitro models-a review'. Together they form a unique fingerprint.

Cite this